Eagle Pharmaceuticals Inc (EGRX.OQ)
EGRX.OQ on NASDAQ Stock Exchange Global Market
68.69USD
24 Sep 2018
68.69USD
24 Sep 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$68.69
$68.69
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
89,801
89,801
52-wk High
$85.66
$85.66
52-wk Low
$48.94
$48.94
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 0.92 | December | 25 Sep 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 1 | 1 | 1 | 1 |
| (2) OUTPERFORM | 3 | 3 | 3 | 3 |
| (3) HOLD | 1 | 1 | 1 | 1 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.00 | 2.00 | 2.00 | 2.00 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 5 | 55.41 | 59.90 | 52.90 | 58.30 |
| Quarter Ending Dec-18 | 5 | 60.94 | 62.70 | 58.30 | 62.00 |
| Year Ending Dec-18 | 5 | 222.28 | 228.10 | 217.10 | 214.92 |
| Year Ending Dec-19 | 5 | 253.40 | 275.71 | 239.90 | 281.67 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 5 | 0.92 | 1.12 | 0.71 | 1.05 |
| Quarter Ending Dec-18 | 5 | 1.33 | 1.53 | 1.09 | 1.21 |
| Year Ending Dec-18 | 5 | 3.49 | 4.05 | 2.15 | 3.96 |
| Year Ending Dec-19 | 5 | 4.40 | 5.10 | 3.86 | 5.72 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Jun-18 | 51.23 | 59.30 | 8.07 | 15.74 |
| Quarter Ending Mar-18 | 48.88 | 46.63 | 2.25 | 4.60 |
| Quarter Ending Dec-17 | 52.91 | 46.78 | 6.12 | 11.58 |
| Quarter Ending Sep-17 | 51.86 | 63.02 | 11.16 | 21.53 |
| Quarter Ending Jun-17 | 52.52 | 50.11 | 2.41 | 4.59 |
| Earnings (per share) | ||||
| Quarter Ending Jun-18 | 0.80 | 0.95 | 0.15 | 18.45 |
| Quarter Ending Mar-18 | 0.69 | 0.53 | 0.16 | 22.63 |
| Quarter Ending Dec-17 | 1.00 | 1.00 | 0.00 | 0.50 |
| Quarter Ending Sep-17 | 0.80 | 1.22 | 0.42 | 52.98 |
| Quarter Ending Jun-17 | 0.51 | 0.28 | 0.23 | 45.10 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 55.41 | 55.41 | 55.41 | 53.57 | 58.30 |
| Quarter Ending Dec-18 | 60.94 | 60.94 | 60.94 | 60.22 | 62.00 |
| Year Ending Dec-18 | 222.28 | 222.28 | 222.28 | 211.62 | 214.92 |
| Year Ending Dec-19 | 253.40 | 257.98 | 257.98 | 250.28 | 281.67 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 0.92 | 0.92 | 0.99 | 1.02 | 1.05 |
| Quarter Ending Dec-18 | 1.33 | 1.33 | 1.40 | 1.34 | 1.21 |
| Year Ending Dec-18 | 3.49 | 3.49 | 3.87 | 3.68 | 3.96 |
| Year Ending Dec-19 | 4.40 | 4.56 | 4.77 | 4.64 | 5.72 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 1 | 0 | 1 |
| Earnings | ||||
| Quarter Ending Sep-18 | 0 | 0 | 0 | 1 |
| Quarter Ending Dec-18 | 0 | 0 | 0 | 1 |
| Year Ending Dec-18 | 0 | 1 | 0 | 2 |
| Year Ending Dec-19 | 0 | 1 | 0 | 2 |
Earnings vs. 
Estimates- BRIEF-Eagle Pharmaceuticals Gets Final FDA Approval For Bendamustine Hydrochloride Ready-To-Dilute Solution In 500Ml Admixture
- BRIEF-Eagle Pharmaceuticals Reports Q1 Adjusted Non-GAAP Earnings Per Share Of $0.53
- BRIEF-Eagle Pharmaceuticals Says CEO Scott Tarriff's 2017 Total Compensation Was $8.04 Mln
- BRIEF-Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By The FDA
- BRIEF-Eagle Pharmaceuticals - Announced Co's Eagle Biologics Division Has Been Issued A New Patent